{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:14:04Z","timestamp":1788520444680,"version":"build-2803163510"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T00:00:00Z","timestamp":1685750400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T00:00:00Z","timestamp":1685750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100014848","name":"Arnold Ventures","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014848","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Rank preserving structural failure time (RPSFT) is a statistical method to correct or adjust for crossover in clinical trials, by estimating the counterfactual effect on overall survival (OS) when control arm patients do not receive the interventional drug when their tumor progresses. We sought to examine the strength of correlation between differences in uncorrected and corrected OS hazard ratios and percentage of crossover, and characterize instances of fundamental and sequential efficacy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In a cross-sectional analysis (2003\u20132023), we reviewed oncology randomized trials that used RPSFT analysis to adjust the OS hazard ratio for patients who crossed over to an anti-cancer drug. We calculated the percentage of RPSFT studies evaluating a drug for fundamental efficacy (with or without a standard of care (SOC)) or sequential efficacy and the correlation between the OS hazard ratio difference (unadjusted and adjusted) and the percentage of crossover.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among 65 studies, the median difference between the uncorrected and corrected OS hazard ratio was \u22120.1 (quartile 1, quartile 3 : \u22120.3 to \u22120.06). The median percentage of crossover was 56% (quartile 1, quartile 3: 37% to 72%). All studies were funded by the industry or had authors who were employees of the industry. Twelve studies (19%) tested a drug\u2019s fundamental efficacy when there was no SOC; 34 studies (52%) tested a drug\u2019s fundamental efficacy when there was already a SOC; and 19 studies (29%) tested a drug\u2019s sequential efficacy. The correlation between the uncorrected and corrected OS hazard ratio difference and the percentage of crossover was 0.44 (95% CI: 0.21 to 0.63).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>RPSFT is a common tactic used by the industry to reinterpret trial results. Nineteen percent of RPSFT use is appropriate. We recognize that while crossover can bias OS results, the allowance and handling of crossover in trials should be limited to appropriate circumstances.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-023-07412-y","type":"journal-article","created":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T06:01:48Z","timestamp":1685772108000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Cross-sectional analysis characterizing the use of rank preserving structural failure time in oncology studies: changes to hazard ratio and frequency of inappropriate use"],"prefix":"10.1186","volume":"24","author":[{"given":"Vinay","family":"Prasad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myung Sun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyson","family":"Haslam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,3]]},"reference":[{"issue":"8","key":"7412_CR1","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1080\/03610929108830654","volume":"20","author":"JM Robins","year":"1991","unstructured":"Robins JM, Tsiatis AA. Correcting for non-compliance in randomized trials using rank preserving structural failure time models. Commun Stat. 1991;20(8):2609\u201331.","journal-title":"Commun Stat"},{"issue":"6","key":"7412_CR2","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/pst.1602","volume":"12","author":"C Watkins","year":"2013","unstructured":"Watkins C, Huang X, Latimer N, Tang Y, Wright EJ. Adjusting overall survival for treatment switches: commonly used methods and practical application. Pharm Stat. 2013;12(6):348\u201357.","journal-title":"Pharm Stat"},{"issue":"4","key":"7412_CR3","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1177\/0272989X18765175","volume":"38","author":"M Ouwens","year":"2018","unstructured":"Ouwens M, Hauch O, Franz\u00e9n S. A validation study of the rank-preserving structural failure time model: confidence intervals and unique, multiple, and erroneous solutions. Med Decis Mak. 2018;38(4):509\u201319.","journal-title":"Med Decis Mak"},{"issue":"3","key":"7412_CR4","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1177\/0272989X13520192","volume":"34","author":"NR Latimer","year":"2014","unstructured":"Latimer NR, Abrams KR, Lambert PC, Crowther MJ, Wailoo AJ, Morden JP, et al. Adjusting survival time estimates to account for treatment switching in randomized controlled trials\u2013an economic evaluation context: methods, limitations, and recommendations. Med Decis Mak. 2014;34(3):387\u2013402.","journal-title":"Med Decis Mak"},{"issue":"5","key":"7412_CR5","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1093\/annonc\/mdy116","volume":"29","author":"A Haslam","year":"2018","unstructured":"Haslam A, Prasad V. When is crossover desirable in cancer drug trials and when is it problematic? Ann Oncol. 2018;29(5):1079\u201381.","journal-title":"Ann Oncol."},{"key":"7412_CR6","unstructured":"Validity of surrogate endpoints in oncology: executive summary of rapid report A10-05. 1.1. Cologne: Institute for Quality and Efficiency in Health Care (IQWiG); 2011. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK198799\/."},{"issue":"5","key":"7412_CR7","first-page":"360","volume":"37","author":"AJ Viera","year":"2005","unstructured":"Viera AJ, Garrett JM. Understanding interobserver agreement: the kappa statistic. Fam Med. 2005;37(5):360\u20133.","journal-title":"Fam Med"},{"issue":"3","key":"7412_CR8","doi-asserted-by":"publisher","first-page":"276","DOI":"10.11613\/BM.2012.031","volume":"22","author":"ML McHugh","year":"2012","unstructured":"McHugh ML. Interrater reliability: the kappa statistic. Biochem Med (Zagreb). 2012;22(3):276\u201382.","journal-title":"Biochem Med (Zagreb)"},{"key":"7412_CR9","volume-title":"R: A language and environment for statistical## computing. R Foundation for Statistical Computing","author":"R Core Team","year":"2021","unstructured":"R Core Team. R: A language and environment for statistical## computing. R Foundation for Statistical Computing. Vienna: R Core Team; 2021."},{"key":"7412_CR10","volume-title":"ggplot2 - Elegant Graphics for Data Analysis","author":"H Wickham","year":"2016","unstructured":"Wickham H. ggplot2 - Elegant Graphics for Data Analysis. 2nd ed. Cham: Springer International Publishing; 2016.","edition":"2"},{"key":"7412_CR11","unstructured":"Garner M, Lemon J, Fellows I, Singh P. irr: Various Coefficients of Interrater Reliability and Agreement. Matthias Gamer; 2019."},{"issue":"4","key":"7412_CR12","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi S, R\u00fccker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22(4):153\u201360.","journal-title":"Evid Based Ment Health"},{"issue":"11","key":"7412_CR13","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.35123","volume":"4","author":"A Haslam","year":"2021","unstructured":"Haslam A, Lythgoe MP, Greenstreet Akman E, Prasad V. Characteristics of Cost-effectiveness Studies for Oncology Drugs Approved in the United States From 2015\u20132020. JAMA Netw Open. 2021;4(11): e2135123.","journal-title":"JAMA Netw Open"},{"issue":"6","key":"7412_CR14","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s40273-014-0145-y","volume":"32","author":"KJ Ishak","year":"2014","unstructured":"Ishak KJ, Proskorovsky I, Korytowsky B, Sandin R, Faivre S, Valle J. Methods for adjusting for bias due to crossover in oncology trials. Pharmacoeconomics. 2014;32(6):533\u201346.","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"7412_CR15","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.jval.2014.06.006","volume":"17","author":"L J\u00f6nsson","year":"2014","unstructured":"J\u00f6nsson L, Sandin R, Ekman M, Ramsberg J, Charbonneau C, Huang X, et al. Analyzing overall survival in randomized controlled trials with crossover and implications for economic evaluation. Value Health. 2014;17(6):707\u201313.","journal-title":"Value Health"},{"issue":"12","key":"7412_CR16","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1001\/jamaoto.2014.1570","volume":"140","author":"T Fojo","year":"2014","unstructured":"Fojo T, Mailankody S, Lo A. Unintended consequences of expensive cancer therapeutics\u2014the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley Lecture. JAMA Otolaryngol Head Neck Surg. 2014;140(12):1225\u201336.","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"11","key":"7412_CR17","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.24406","volume":"3","author":"A Ladanie","year":"2020","unstructured":"Ladanie A, Schmitt AM, Speich B, Naudet F, Agarwal A, Pereira TV, et al. Clinical trial evidence supporting US food and drug administration approval of novel cancer therapies between 2000 and 2016. JAMA Netw Open. 2020;3(11): e2024406.","journal-title":"JAMA Netw Open"},{"issue":"8","key":"7412_CR18","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1200\/JCO.2007.13.5335","volume":"26","author":"CK Daugherty","year":"2008","unstructured":"Daugherty CK, Ratain MJ, Emanuel EJ, Farrell AT, Schilsky RL. Ethical, scientific, and regulatory perspectives regarding the use of placebos in cancer clinical trials. J Clin Oncol. 2008;26(8):1371\u20138.","journal-title":"J Clin Oncol"},{"issue":"8","key":"7412_CR19","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1177\/0962280218780856","volume":"28","author":"NR Latimer","year":"2019","unstructured":"Latimer NR, White IR, Abrams KR, Siebert U. Causal inference for long-term survival in randomised trials with treatment switching: Should re-censoring be applied when estimating counterfactual survival times? Stat Methods Med Res. 2019;28(8):2475\u201393.","journal-title":"Stat Methods Med Res"},{"key":"7412_CR20","unstructured":"US Food and Drug Administration. Center for drug evaluation and research. Lenvatinib: NDA 206947. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/206947orig1s000clinpharmr.pdf."},{"key":"7412_CR21","unstructured":"US Food and Drug Administration. Center for drug evaluation and research. mobocertinib: IND 126721. 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2021\/215310Orig1s000Approv.pdf."},{"key":"7412_CR22","unstructured":"US Food and Drug Administration. Center for drug evaluation and research. POTELIGEO (mogamulizumab-kpkc): BLA 761051. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/761051Orig1s000Approv.pdf."},{"issue":"5","key":"7412_CR23","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1213\/ANE.0000000000002864","volume":"126","author":"P Schober","year":"2018","unstructured":"Schober P, Boer C, Schwarte LA. Correlation Coefficients. Anesthesia & Analgesia. 2018;126(5):1763\u20138.","journal-title":"Anesthesia & Analgesia."},{"issue":"3","key":"7412_CR24","first-page":"69","volume":"24","author":"MM Mukaka","year":"2012","unstructured":"Mukaka MM. Statistics corner: a guide to appropriate use of correlation coefficient in medical research. Malawi Med J. 2012;24(3):69\u201371.","journal-title":"Malawi Med J."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07412-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-023-07412-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07412-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T06:03:03Z","timestamp":1685772183000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-023-07412-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,3]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["7412"],"URL":"https:\/\/doi.org\/10.1186\/s13063-023-07412-y","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,3]]},"assertion":[{"value":"20 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"In accordance with 45 CFR \u00a746.102(f), this study was not submitted for institutional review board approval because it involved publicly available data and did not involve individual patient data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Vinay Prasad\u2019s Disclosures. (Research funding) Arnold Ventures (Royalties) Johns Hopkins Press, Medscape, and MedPage (Honoraria) Grand Rounds\/lectures from universities, medical centers, non-profits, and professional societies. (Consulting) UnitedHealthcare and OptumRX. (Other) Plenary Session podcast has Patreon backers, YouTube, and Substack. All other authors have no financial nor non-financial conflicts of interest to report.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"373"}}